---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-073594"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:45:36.272274+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Disc Medicine reports FY2025 net loss $212.2M; receives CRL for bitopertin; cash runway into 2029

## Summary
- Net loss of $212.2M for FY2025, up from $109.4M in FY2024; driven by higher R&D and SG&A costs.
- Cash, cash equivalents and marketable securities of $791.2M as of Dec 31, 2025, up from $489.9M.
- FDA issued Complete Response Letter for bitopertin in EPP in Feb 2026; Phase 3 APOLLO topline data expected Q4 2026.
- Phase 2 data for DISC-0974 in MF anemia showed durable hemoglobin benefits across subgroups at ASH.
- DISC-3405 Phase 2 in PV and Phase 1b in SCD ongoing; initial data expected 2H 2026.

## SEC filing metadata
- accession: 0001193125-26-073594
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/0001193125-26-073594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312526073594/iron-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-073594
- JSON: https://secwatch.observer/filing/0001193125-26-073594.json
- Plain text: https://secwatch.observer/filing/0001193125-26-073594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.